Concord Healthcare (2453) Releases Nomination Committee Terms of Reference

Bulletin Express
2025/10/31

Concord Healthcare Group Co., Ltd. (Stock code: 2453) recently announced the Terms of Reference for its Nomination Committee under the Board of Directors. According to the released document, the newly established Nomination Committee is primarily entrusted with determining selection procedures and standards for directors and senior management, conducting preliminary reviews of candidate qualifications, and making recommendations to the Board.

The document emphasizes that the Committee comprises at least three directors, and the majority must be independent non-executive directors. The Committee chairman, who is responsible for leading its work, must be either an independent non-executive director or the Board chairman. In cases where the chairman cannot perform duties, another independent non-executive director will be appointed to assume those responsibilities.

Core responsibilities include reviewing the composition of the Board to ensure a balanced mix of skills and experience, identifying and assessing potential director and senior management candidates, and evaluating the independence of independent non-executive directors. Additionally, the Committee can engage external experts if required, and its decisions are subject to Board approval. Meetings are to be held at least once a year, with additional sessions convened as needed.

The Terms of Reference also outline rules for abstention when conflicts of interest arise and specify documentation requirements for Committee meetings. Any recommendations not adopted by the Board must be formally recorded with an explanation. The Terms of Reference take effect upon approval by the Board, serving as the foundation for enhancing corporate governance and ensuring a consistent approach to director and senior management appointments.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10